Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone/naloxone prolonged-release versus oxycodone prolonged-release for cancer-related pain
ACTRN12619001282178Phase 4Terminated
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oxycodone + naloxone and oxycodone in cancer pain (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Average pain over the last 24 hours at Week 5. Started Nov 2019; status: terminated.
02
Drugs
oxycodone + naloxoneoxycodone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ACTRN12619001282178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001282178.